Not only a skin disease — joints and metabolism are involved
Quick answer
Psoriasis arises when immune signalling drives skin cells to divide far too fast, producing thick scaly plaques. A share of patients also develop arthritis, and metabolic risk runs higher than average. The cell therapy idea is systemic immune rebalancing rather than treating skin alone.
The central inflammatory axis in psoriasis is IL-17 and IL-23, the target of modern biologics that work very well. Anyone who has not tried them should discuss that with a dermatologist before turning to investigational options.
MSCs are studied here because they can dampen Th17 cells, the source of IL-17. Outcomes are scored with PASI, which grades plaque thickness, redness and scaling, giving a numeric before-and-after comparison.
Do not overlook the triggers you control: stress, smoking, alcohol, excess weight and throat infections. Managing them genuinely reduces flare frequency at almost no cost.
No — it is the patient's own immune process.
It typically relapses and remits, so the aim is control and fewer flares rather than permanent cessation.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesBanobagi
Related topics: Joints & immunity